The primary role of vitamin K2 is to activate vitamin K-dependent proteins (VKDPs) so they can perform essential functions in the body, such as supporting bone production, cardiovascular health, energy production and brain health.
Given these major health benefits it could be said that Vitamin K2 is one of the most important dietary supplements available to us, because Vitamin K2 is not typically found in sufficient quantities in our diet.
Cura Vitamin K2-7+ is the first vitamin K2 supplement available in the UK retail market to use the pharmaceutical grade MenaQuinGold® K2-7 ingredient. This Cura Nutrition formulation has been created to include a therapeutic dose of 320 mcg of vitamin K2-7, plus 200 mcg of Vitamin K1 and the necessary co-factors, magnesium and zinc to allow these K vitamins to function at their optimal level.
If someone is deficient in vitamin K1 (and most people are), and they take a vitamin K2 supplement, the liver will essentially steal the K2 to satisfy its own needs. Therefore, Cura Vitamin K2-7+ includes enough K1 in the formula to satisfy the liver’s needs, even in the most depleted individuals. This addition of vitamin K1, ensures that the vitamin K2 is then available for the vital functions that it needs to perform in the body.
Whilst many vitamin K2 products on the market are either synthetic or soy-based the MenaQuinGold® K2-7 ingredient used in Cura Vitamin K2-7+ is sourced from a pharmaceutical grade ingredient that has been manufactured from fermented chickpeas.
For adults: Take 2 capsules daily with a meal, or as directed by your doctor or healthcare practitioner.
For children over 8 years of age: If the child can safely swallow the capsule take 1 capsule daily with a meal, or as directed by your doctor or healthcare practitioner. If the child cannot easily swallow the capsule twist open the capsule and sprinkle contents onto food.
GELEJINSE J, VERMEER C, GROBBEE D, ET AL. Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: The Rotterdam Study. J Nutr. 2004; 134:3100-3105.
BEULENS J, BOTS M, ATSMA F, ET AL. High dietary menaquinone intake is associated with reduced coronary calcification. Atherosclerosis. 2009;203:489-493.
BOLLAND M, AVENELL A, BARON J, ET AL. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: Meta-analysis. British Medical Journal. 2010; 341:3691.
BEULENS JW, VAN DER AD, GROBBEE DE, SLUIJS I, SPIJKERMAN AM, VAN DER SCHOUW YT. Dietary phylloquinone and menaquinones intakes and risk of type 2 diabetes. Diabetes Care. 2010 Aug;33(8):1699-705.
IWAMOTO J, SEKI A, SATO Y, MATSUMOTO H, TAKEDA T, YEH JK. Vitamin K(2) prevents hyperglycemia and cancellous osteopenia in rats with streptozotocin-induced type 1 diabetes. Calcif Tissue Int. 2011 Feb;88(2):162-8.
CHOI HJ, YU J, CHOI H, ET AL. Vitamin K2 supplementation improves insulin sensitivity via osteocalcin metabolism: a placebo-controlled trial. Diabetes Care. 2011 Sep;34(9):e147.
SAMYKUTTY A, SHETTY AV, DAKSHINAMOORTHY G, ET AL. Vitamin k2, a naturally occurring menaquinone, exerts therapeutic effects on both hormone-dependent and hormone-independent prostate cancer cells. Evid Based Complement Alternat Med. 2013;2013:287358.
KIELY, MAEVE ET AL. Real-time cell analysis of the inhibitory effect of vitamin K2 on adhesion and proliferation of breast cancer cells. Nutr Res. 2015;35(8): 736-743.
MIZUTA T, OZAKI I, EGUCHI Y, ET AL. The effect of menatetrenone, a vitamin K2 analog, on disease recurrence and survival in patients with hepatocellular carcinoma after curative treatment: a pilot study. Cancer. 2006 Feb 15;106(4):867-72.
KAIPPARETTU BA, MA Y, PARK JH, ET AL. Crosstalk from non-cancerous mitochondria can inhibit tumor properties of metastatic cells by suppressing oncogenic pathways. PLoS ONE. 2013; 8:e61747